What's Next for the Biomedical Community?

The first is potentially the first approval of a CRISPR gene editing therapy, and now that's specifically going to be a therapy to treat beta thalassemia and sickle cell disease. The US regulators will announce in early January whether this drug can become available. And there's another drug which scientists and many people around the world will be watching closely that is currently sitting with regulators - an anti-Alzheimer's antibody.